XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
  AIDS
  Influenza
  MRSA
  Tuberculosis
  Shigella
  HCV
  SARS
  Ebola
  Dengue
  Malaria
  Pertussis
  Mumps
  Prion Diseases
  Small Pox
  Anthrax
  Leishmaniasis
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
 
 India
Search

Last Updated: Nov 18, 2006 - 12:32:53 PM
Research Article

Tuberculosis Channel
subscribe to Tuberculosis newsletter

Latest Research : Infectious Diseases : Tuberculosis

   DISCUSS   |   EMAIL   |   PRINT
Tuberculosis Still a Risk for Patients on Anti-retrovirals
Nov 12, 2005 - 7:58:00 PM, Reviewed by: Dr.

HIV-infected American and European patients who are �exposed to someone with tuberculosis, for example in a hospital setting, are at increased risk of acquiring tuberculosis infection and of developing active tuberculosis within a short time, usually six months to one year,�

 
People taking highly active antiretroviral therapy (HAART) for HIV infection remain susceptible to tuberculosis, though the risk is lower than for HIV-infected patients not on HAART, according to an article in the Dec. 15 issue of Clinical Infectious Diseases, now available online.

Opportunistic infections such as tuberculosis (TB) can be fatal for immunocompromised patients. HAART not only reduces the viral load of HIV, but it also often helps to keep other infections such as TB under control. In fact, previous studies indicate that HAART can reduce the risk of TB in HIV patients by 70 to 90 percent. Although HIV-infected people living in industrialized nations are at lower risk of TB than those living in resource-poor countries, it continues to be a significant problem for HIV-infected people everywhere.

A group of European and American researchers followed patients with HIV for three years after they began HAART. The rate of tuberculosis was highest within the first three months of therapy, but declined after longer HAART exposure. Patients� risk of developing tuberculosis more than doubled if HAART did not successfully control their HIV. Patients were also more likely to develop TB if they were more immunodeficient when they started taking HAART.

HIV-infected patients from industrialized nations might develop TB if they were exposed to the tuberculosis organism in the past, especially for those emigrating from resource-poor countries. Their weakened immune status can allow reactivation of latent TB infection, according to lead author Enrico Girardi, MD, of the Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani in Rome.

But they don�t necessarily have to leave the country to contract TB. HIV-infected American and European patients who are �exposed to someone with tuberculosis, for example in a hospital setting, are at increased risk of acquiring tuberculosis infection and of developing active tuberculosis within a short time, usually six months to one year,� Dr. Girardi said.

Since TB is a potentially deadly opportunistic infection for patients with HIV, doctors need to be aware of the risk and take certain precautionary measures. �HIV-infected patients, even when treated with HAART, remain at increased risk of developing tuberculosis,� Dr. Girardi said. �Thus, physicians caring for patients with HIV should continue to screen for and to treat latent tuberculosis infection in their patients, even if they have minor levels of immune suppression or are successfully treated with HAART.� Health care settings should also maintain strict control measures to prevent the spread of tuberculosis to patients being treated for HIV, Dr. Girardi added.

In an accompanying editorial commentary, Stephen D. Lawn, MRCP, MD, and Robin Wood, MBChB, of the Desmond Tutu HIV Centre in South Africa indicated similar findings (unpublished) related to patients� immunological response to HAART and subsequent development of TB. The commentary concludes that HIV-infected patients� risk for infection with TB �remains elevated among those receiving treatment in both high- and low-income countries.�
 

- Dec. 15 issue of Clinical Infectious Diseases, now available online
 

www.idsociety.org

 
Subscribe to Tuberculosis Newsletter
E-mail Address:

 

Founded in 1979, Clinical Infectious Diseases publishes clinical articles twice monthly in a variety of areas of infectious disease, and is one of the most highly regarded journals in this specialty. It is published under the auspices of the Infectious Diseases Society of America (IDSA). Based in Alexandria, Virginia, IDSA is a professional society representing more than 8,000 physicians and scientists who specialize in infectious diseases. Nested within the IDSA, the HIV Medicine Association (HIVMA) is the professional home for more than 2,700 physicians, scientists and other health care professionals dedicated to the field of HIV/AIDS. HIVMA promotes quality in HIV care and advocates policies that ensure a comprehensive and humane response to the AIDS pandemic informed by science and social justice. For more information, visit www.idsociety.org.

Related Tuberculosis News

Emergence of highly drug-resistant tuberculosis strains requires urgent action
Treating populations infected with HIV and latent TB could speed the emergence of drug-resistant TB
Solution to TB epidemic may lie in protective Heme oxygenase 1 protein
Explaining Why People of African Descent Are More Vulnerable to TB
Indian Scientists Identify Key Genes in Tuberculosis Infection
PA-824 holds promise for shortening the TB treatment regimen
DC-SIGN expressing alveolar macrophages are preferentially targeted by M. tuberculosis
Tuberculosis Still a Risk for Patients on Anti-retrovirals
Evolutionary history of tuberculosis is shaped by human migration patterns
TB vaccines will fail in developing countries


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us